Advanced nanoscale carrier-based approaches to overcome biopharmaceutical issues associated with anticancer drug 'Etoposide'.
Etoposide (ETS), topoisomerase-II inhibitor, is a first-line anticancer therapeutics used in diverse cancer types. However, the therapeutic potential of this molecule has mainly impeded due to its detrimental toxicity profile, unfavorable rejection by the cancer cells due to P-glycoprotein (P-gp) efflux activity, and rapid hepatic clearance through extensive metabolism by Cytochrome-P450. To increase the therapeutic potency without significant adverse effects, the implication of novel ETS-nanoformulation strategies have recommended mainly. Nanomedicine based nanoformulation approaches based on nanoparticles (NPs), dendrimers, carbon-nanotubes (CNTs), liposomes, polymeric micelles, emulsions, dendrimers, solid-lipid NPs, etc offers immense potential opportunities to improve the therapeutic potential of pharmaceutically problematic drugs. This review provides an up-to-date argument on the work done in the field of nanomedicine to resolve pharmacokinetic and pharmacodynamic issues associated with ETS. The review also expounds the progress in regards to the regulatory, patenting and clinical trials related to the innovative formulation aspects of ETS.
['Choudhury|Hira|H|', 'Maheshwari|Rahul|R|', 'Pandey|Manisha|M|', 'Tekade|Muktika|M|', 'Gorain|Bapi|B|', 'Tekade|Rakesh Kumar|RK|']
D000818:Animals D004337:Drug Carriers D004355:Drug Stability D004705:Endocytosis D005047:Etoposide D006207:Half-Life D006801:Humans D053758:Nanoparticles D012995:Solubility D059005:Topoisomerase II Inhibitors
Patent and clinical trials Etoposide delivery Etoposide solubility Etoposide toxicity Pharmacological advances